Skip to content

Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors

AutoLITT™ FIM Trial - A Prospective First-In-Man (FIM) Safety Trial of the AutoLITT Laser Treatment of Recurrent/Progressive Brain Tumors

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00747253
Enrollment
10
Registered
2008-09-05
Start date
2008-08-31
Completion date
2010-04-30
Last updated
2021-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Cancer, Brain Neoplasm, Brain Tumor, Brain Tumor, Recurrent, Glioblastoma Multiforme, Recurrent Glioblastoma Multiforme

Keywords

laser interstitial thermal therapy, laser therapy, thermal therapy, brain tumors, recurrent brain tumor, progressive brain tumor, glioblastoma multiforme tumor

Brief summary

The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).

Interventions

DEVICEAutoLITT system

laser treatment with the AutoLITT system

Sponsors

Monteris Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Previous diagnosis of GBM treated with radiotherapy with or without surgical resection and/or chemotherapy * Clinical/radiographic suspicion of tumor recurrence/progression

Exclusion criteria

* Previous treatment of target GBM with stereotactic radiosurgery, brachytherapy, or carmustine impregnated wafers (Gliadel).

Design outcomes

Primary

MeasureTime frame
Primary endpoint is safety, as determined by absence of severe clinical toxicity or procedure-related neurological deficits14 days post-surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 23, 2026